Cargando…
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
BACKGROUND: Standard therapy for glioblastoma includes surgery, radiotherapy, and temozolomide. This Phase 3 trial evaluates the addition of an autologous tumor lysate-pulsed dendritic cell vaccine (DCVax(®)-L) to standard therapy for newly diagnosed glioblastoma. METHODS: After surgery and chemorad...
Ejemplares similares
-
Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
por: Liau, Linda M., et al.
Publicado: (2018) -
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial
por: Liau, Linda M., et al.
Publicado: (2022) -
Dimorphic glioblastoma with glial and epithelioid phenotypes: Clonal evolution and immune selection
por: Mondia, Mark Willy L., et al.
Publicado: (2023) -
Use of FLOSEAL® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy
por: Bomba, Hunter N., et al.
Publicado: (2022) -
SUN-443 Surgical Management of Cystic Prolactinomas
por: Nevzati, Edin, et al.
Publicado: (2019)